Corporate Banner
Satellite Banner
Technology
Networks
Scientific Communities
 
Become a Member | Sign in
Home>News>This Article
  News
Return

Sanofi, Takeda form Diabetes Collaboration in Japan

Published: Wednesday, July 02, 2014
Last Updated: Wednesday, July 02, 2014
Bookmark and Share
Companies have entered into an agreement to build a collaborative system within Japan in the field of diabetes awareness and education.

In the long history of diabetes treatment, both Sanofi and Takeda have brought to market numerous therapeutic drugs to treat diabetes over the years and have built up abundant knowledge and experience. By establishing this partnership, the two companies aim to offer more treatment solutions and information to healthcare professionals addressing diversified medical needs of people with diabetes. Through the agreement the two companies will also be able to expand educational activities regarding the disease.

The 2012 National Health and Nutrition Survey by the Ministry of Health, Labour and Welfare estimated that some 9.5 million Japanese are strongly suspected of having diabetes. The Ministry also predicts that the number of Japanese with diabetes will reach 15 million by 2025. One in every four people in Japan is said to be pre-diabetic, and of those who are strongly suspected of be diabetic, approximately 30% have never received sufficient treatment, according to the survey results.

To address challenges faced by diabetes patients, their families, healthcare professionals and the government, the two companies will uphold a vision that we aim to become the most trusted partners of healthcare professionals and diabetes patients in Japan. The agreement will develop solutions focused in the following three areas:

Raise public awareness of diabetes and educate on how to prevent diabetes, including lifestyle management.

Provide educational support to patients to emphasize the importance of dietary and exercise therapies and appropriate drug treatment.

Provide healthcare professionals with comprehensive information on diabetes care.

"Diabetes is too large and complex an issue for a single company, single doctor or single government to resolve on its own. Closely aligning efforts at all levels is essential to achieve a breakthrough in preventing, diagnosing and treating diabetes. To this end, we are excited to join forces with Takeda, Japan's largest pharmaceutical company and a leader in diabetes, to create this new and unique agreement to expand existing and create new approaches to improving patient care and, ultimately, improving outcomes for Japanese living with diabetes,” stated Jez Moulding, President and Representative Director, Sanofi K.K., Senior Vice President, Japan & Pacific Region

"Many effective solutions for diabetes treatment have been brought to market in the last 20 years, but many patients are still unable to meet their blood sugar control targets and many still experience complications," said Masato Iwasaki, Ph.D., Senior Vice President, Pharmaceutical Marketing Division of Takeda. "This close agreement between two leading companies in the field of diabetes holds great significance for finding solutions for diabetes treatments based on a mutual understanding of each other's vision and therapies. With such an excellent partner, we are confident that we will be better equipped to facilitate diabetes care for patients based on their individual needs."

The agreement involves no initial payment or other compensation. The manufacturing and marketing rights holder of each company’s respective products will conduct their own product promotion and collection and dissemination of product safety information.

In addition to this agreement, both parties agree to start formulation development studies of a fixed dose combination of tofogliflozin (product name: Apleway®) and alogliptin (product name: Nesina®).


Further Information

Join For Free

Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 3,100+ scientific posters on ePosters
  • More Than 4,500+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

Takeda Receives $38 Million Grant from the Gates Foundation
The grant has been awareded to support polio eradication in developing countries.
Wednesday, May 11, 2016
Takeda, NsGene Partner
Takeda Pharmaceutical and NsGene, Inc. have announced a research agreement to develop encapsulated cell therapies for the potential treatment of Parkinson’s disease.
Thursday, January 14, 2016
Takeda Acquires U.S. Biologics Manufacturing Facility
Takeda Pharmaceutical Company Limited has announced the acquisition of a biologics manufacturing facility located in Brooklyn Park, Minnesota, U.S., from Baxalta US Inc.
Thursday, January 07, 2016
Takeda, Enterome Enter Drug Discovery Collaboration
Takeda and Enterome have announced they have entered into a strategic drug discovery collaboration to research and develop potential new therapeutics directed at microbiome targets thought to play crucial roles in gastrointestinal disorders, including inflammatory bowel diseases (e.g. ulcerative colitis) and motility disorders (e.g. irritable bowel syndrome).
Thursday, January 07, 2016
Takeda, Cour Partner
Takeda and Cour have announced a partnership to research and develop novel immune modulating therapies for the potential treatment of celiac disease.
Wednesday, December 09, 2015
Gencia and Takeda Partner On Mitochondrial Therapeutics
The companies announced have a partnership to develop a new class of small molecule drugs as potential treatments for hematological and inflammatory diseases.
Friday, September 11, 2015
Takeda, Sanford-Burnham Launch Heart Failure Collaboration
The partners will study the potential role of several gene regulatory proteins as targets for new treatments.
Friday, May 29, 2015
Takeda Licenses Rights to Use ImmunoGen's ADC Technology
To develop and commercialize targeted anticancer therapeutics to up to two undisclosed targets.
Friday, March 27, 2015
Takeda Announces Formalization of Takeda Oncology
Enhance discovery, development and global commercialization of cancer medicines.
Friday, December 12, 2014
Takeda Buys Vaccines Specialist Inviragen
Obtains promising vaccine candidates against dengue and hand, foot and mouth disease, advancing Takeda's commitment to vaccines and global health.
Thursday, May 09, 2013
Takeda to Acquire URL Pharma
Acquisition expands U.S. business, leadership in gout.
Thursday, April 12, 2012
Molecular Cell Publishes Data on A Novel Form of Enzyme Inhibition of A Protein Homeostasis Target
MLN4924 is said to be the first compound shown to selectively inhibit important cancer target.
Monday, January 18, 2010
Millennium Initiates Phase II Trial for Diffuse Large B-Cell Lymphoma
Large, multi-center study to investigate VELCADE in genomically defined subtype of NHL.
Monday, October 26, 2009
CBP501 Enters Phase II Trials for the Treatment of Non-Small Cell Lung Cancer
CanBas and Takeda announce the advancement of CBP501 into Phase II clinical trials for the treatment of patients with non-small cell lung cancer.
Monday, July 13, 2009
Scientific News
The Rise of 3D Cell Culture and in vitro Model Systems for Drug Discovery and Toxicology
An overview of the current technology and the challenges and benefits over 2D cell culture models plus some of the latest advances relating to human health research.
New NIH-EPA Research Centers to Study Environmental Health Disparities
Scientists will partner with community organizations to study these concerns and develop culturally appropriate ways to reduce exposure to harmful environmental conditions.
Structure of Essential Digestive Enzyme Uncovered
Using a powerful combination of techniques from biophysics to mathematics, researchers have revealed new insights into the mechanism of a liver enzyme that is critical for human health.
Air Pollution Linked to Heart Disease
10-year project revealed air pollutants accelerate plaque build-up in arteries to the heart.
Getting a Better Look at How HIV Infects and Takes Over its Host Cells
A new approach, developed by a team of researchers led by The Rockefeller University and The Aaron Diamond AIDS Research Center (ADARC), offers an unprecedented view of how a virus infects and appropriates a host cell, step by step.
Following Tricky Triclosan
Antibacterial product flows through streams, crops.
Vitamin A May Help Improve Pancreatic Cancer Chemotherapy
The addition of high doses of a form of vitamin A could help make chemotherapy more successful in treating pancreatic cancer, according to an early study by Queen Mary University of London (QMUL).
Poverty Marks a Gene, Predicting Depression
New study of high-risk teens reveals a biological pathway for depression.
World’s Largest Coral Gene Database
‘Genetic toolkit’ will help shed light on which species survive climate change.
A Boost for Regenerative Medicine
Growing tissues and organs in the lab for transplantation into patients could become easier after scientists discovered an effective way to produce three-dimensional networks of blood vessels, vital for tissue survival yet a current stumbling block in regenerative medicine.
Scroll Up
Scroll Down
Skyscraper Banner

Skyscraper Banner
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
3,100+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
4,500+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FOR FREE!